NeuroSearch AS Names Patrik Dahlen as the Company's New CEO

NeuroSearch AS Names Patrik Dahlen as the Company's New CEO

COPENHAGEN, 24 August 2010 - Today, NeuroSearch A/S (NEUR), a leading CNS focused and European based biopharmaceutical company announced the appointment of Patrik Dahlen as new CEO of the company. With effect from 15 September 2010, Patrik Dahlen will replace CEO Flemming Pedersen, who resigns to take up a new position in another company.

Patrik Dahlen (born 1962) brings more than 17 years of broad-based managerial experience from the international life science industry, covering drug discovery, product development, production, marketing and sales. His former career includes nearly eight years with PerkinElmer (NYSE: PKI), where he built the company's global Life Sciences unit and held positions as President and Senior Vice President with basis in the US. Further, Patrik Dahlen has served more than three years as the CEO of Dako, a world-leading cancer diagnostics company with 1,000 employees and over DKK 1.5 billion in revenues, where he in his first two years streamlined the company and repositioned it for cancer diagnostics leadership. Patrik Dahlen holds a PhD in Biochemistry and he joins NeuroSearch from a current position as CEO in Chempaq A/S. See attached CV resume for additional information on Patrik Dahlen's background and competences.

Thomas Hofman-Bang, Chairman of the Board in NeuroSearch, commented:

"I am very pleased to be able to announce the appointment of Patrik Dahlen as the new CEO of NeuroSearch. Patrik Dahlen has ample experience in the effective management of commercially driven organisations combined with a comprehensive understanding of R&D based business entities. I am convinced that he holds the exact right competences to ensure the continued successful development of NeuroSearch towards commercialisation and profitability."

Patrik Dahlen, newly appointed CEO of NeuroSearch, commented;

"I am excited about the opportunity to take part in the continued development of NeuroSearch with a view to building a long term profitable specialty pharma company. NeuroSearch stands today as a renowned R&D driven CNS drug company, with highly promising potential for further value creation. It is an exciting time to join NeuroSearch as Huntexil® is nearing the commercialisation phase and the company will need to start accelerating the development of sales and marketing competencies."

 Thomas Hofman-Bang

Chairman of the Board

Contact persons

Thomas Hofman-Bang, Chairman of the Board, telephone; +45 4348 3202

 Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications, telephone; +45 4460 8212 or +45 4017 5103

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.